16523-28-7

FMP-API-1 is an A-kinase anchoring protein (AKAP)-PKA interaction inhibitor. FMP-API-1 binds to the allosteric site of PKA R subunits and increases the activity of PKA and AQP2 in PKA-knockout cell lines of renal cortical collecting ducts (mpkCCD cells). FMP-API-1 has the potential for the study of nephrogenic diabetes insipidus (NDI)[1][2].

[1] Ando F. Activation of AQP2 water channels by protein kinase A: therapeutic strategies for congenital nephrogenic diabetes insipidus. Clin Exp Nephrol. 2021 Oct;25(10):1051-1056. DOI:10.1007/s10157-021-02108-6
[2] Fumiaki Ando, et al. AKAPs-PKA disruptors increase AQP2 activity independently of vasopressin in a model of nephrogenic diabetes insipidus. Nat Commun. 2018 Apr 12;9(1):1411. DOI:10.1038/s41467-018-03771-2